8-K: Harrow Acquires TYRVAYA Nasal Spray for Dry Eye Disease

Harrow, Inc. announced its definitive agreement to acquire the global rights to TYRVAYA (varenicline solution) nasal spray from Viatris Inc., expanding its dry eye disease portfolio.

Summary

• Harrow, Inc. has entered into an Asset Purchase Agreement to acquire the global rights to TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris Inc.
• TYRVAYA is a cholinergic agonist indicated for the treatment of dry eye disease (DED) and is approved in the U.S., China, and Taiwan, with applications pending elsewhere.
• The acquisition aims to complement Harrow's existing VEVYE franchise by offering a different mechanism of action for DED treatment.
• Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments based on net sales.
• The transaction is expected to close in the second half of 2026, subject to customary closing conditions.
• The company expects to fund the upfront payment with existing cash on hand.
• The acquisition is expected to be financially accretive shortly after closing and leverage Harrow's existing infrastructure.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating strategic growth and portfolio expansion in a key therapeutic area.

Positives

• Expands Harrow's dry eye disease portfolio with a differentiated product, TYRVAYA.
• TYRVAYA offers a unique nasal spray delivery method, avoiding ocular instillation-site reactions and offering a drop-free option for patients, including contact lens wearers.
• The acquisition complements the VEVYE franchise by addressing DED with a different mechanism of action (stimulating basal tear production vs. VEVYE addressing inflammation).
• Leverages Harrow's existing sales, marketing, and reimbursement infrastructure.
• Expected to strengthen the company through the addition of select talent from Viatris.
• The transaction is expected to be financially accretive shortly after closing.
• TYRVAYA comes with existing promotional awareness and a base of prescribers, representing a 'plug and play' addition to Harrow's offerings.
• Enhances Harrow's ability to offer physicians a comprehensive set of tools for managing dry eye disease.

Negatives

• The total consideration could reach up to $100 million ($30 million cash upfront + up to $70 million in contingent milestone payments).
• The acquisition is subject to customary closing conditions, and there is no assurance it will be completed on the anticipated timeline or at all.
• Potential for contingent milestone payments to increase the total cost if sales targets are met.

Risks

• The Acquisition may not be completed on the anticipated timeline or at all.
• The anticipated benefits of the Acquisition may not be realized.
• Risks related to the integration of TYRVAYA into Harrow's existing portfolio and operations.
• Competition from other pharmaceutical companies in the dry eye disease market.
• Potential for regulatory or legal challenges related to the product or its marketing.
• The success of contingent milestone payments is dependent on achieving specified annual net sales thresholds for TYRVAYA.
• Risks associated with the broader pharmaceutical and healthcare industry, including economic conditions and supply chain challenges.

Future Outlook

The company expects the Closing to occur in the second half of 2026. The acquisition is expected to be financially accretive shortly after the transaction closes. Harrow anticipates that the combined VEVYE and TYRVAYA offerings will strengthen its foundation and accelerate growth across its dry eye franchise.

Management Comments

• "This acquisition expands Harrows dry eye portfolio, complementing the Companys flagship VEVYE franchise by addressing dry eye disease with a different underlying mechanism of action."
• "Because TYRVAYA is delivered as a nasal spray rather than an eye drop, it avoids ocular instillation-site reactions entirely; its prescribing information includes no contraindications and no warnings or precautions, and its most common adverse reaction, sneezing, is transient."
• "This acquisition is about Harrows commitment to offer the most comprehensive set of tools to help U.S. ophthalmologists and optometrists manage their patients dry eye disease."
• "While VEVYE remains the cornerstone of our dry eye franchise, TYRVAYA strengthens our foundation by expanding the number of patients and physicians we can serve through a complementary mechanism of action: VEVYE addresses the inflammatory component of dry eye disease, and TYRVAYA stimulates the bodys natural basal tear production literally within minutes of the first dose."
• "Also, as the first and only FDA-approved nasal spray for dry eye disease, TYRVAYA offers the 45+ million U.S. contact lens wearers a drop-free treatment option because it is the only prescription therapy that does not require lens removal before administration."
• "We believe Harrow is now uniquely positioned to accelerate growth across our dry eye franchise by providing physicians with greater flexibility to individualize treatment for their patients."
• "This transaction is another example of the disciplined approach to capital allocation and business development that has become a hallmark of Harrows growth strategy."
• "Moreover, TYRVAYA is plug and play with our existing cost structure, and given the existing stream of revenue TYRVAYA produces, is expected to be financially accretive shortly after the transaction closes."
• "There are literally thousands of physicians writing TYRVAYA today, and the brand comes to us with real promotional awareness already built that is a rare thing to be able to acquire."
• "Every physician interaction now carries two branded prescription options instead of one, which we expect to raise the productivity of our commercial organization and strengthen the growth trajectory of both VEVYE and TYRVAYA, as well as our entire ocular surface franchise."

Industry Context

StockSavvy.ai notes that this acquisition aligns with a trend in the pharmaceutical industry of companies seeking to expand their portfolios in specialized therapeutic areas, particularly in ophthalmology. The focus on differentiated delivery mechanisms and complementary mechanisms of action for chronic conditions like dry eye disease is a key strategy for market penetration and patient retention.

Stakeholder Impact

• Shareholders: Potential for increased revenue and profitability due to portfolio expansion and expected financial accretion.
• Patients: Access to a new, differentiated treatment option for dry eye disease, particularly those who prefer a drop-free method or wear contact lenses.
• Physicians: Expanded treatment options for managing dry eye disease, allowing for more personalized patient care.
• Employees: Potential for integration of talent from Viatris and opportunities within an expanded Harrow organization.
• Suppliers/Creditors: No immediate direct impact indicated, though long-term financial health of Harrow will be relevant.

Next Steps

• Complete the acquisition of TYRVAYA from Viatris, expected in the second half of 2026.
• Enter into certain ancillary agreements, including a transition services agreement, in connection with the Closing.
• File the Purchase Agreement as an exhibit to Harrow's Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2026.
• Integrate TYRVAYA into Harrow's existing dry eye franchise and leverage existing sales and marketing infrastructure.
• Promote TYRVAYA alongside VEVYE to physicians and patients.

Key Dates

Recommendation

The acquisition is a positive strategic move that expands Harrow's key franchise and is expected to be accretive. However, the contingent nature of a significant portion of the purchase price and the inherent risks in any acquisition (completion, integration, market adoption) warrant a 'hold' rating until the transaction closes and its initial impact is clearer. The company's ability to successfully integrate and grow TYRVAYA will be critical.

Keywords

Dry Eye Disease, TYRVAYA, Viatris, Asset Purchase Agreement, Ophthalmic, Nasal Spray, Varenicline Solution, VEVYE